Kempharm - ZVRA EV/EBITDA Multiple

Corporate emblem and logo of Kempharm (ZVRA)

The visualized EV/EBITDA market trend for Zevra Therapeutics (ZVRA) is recorded at 7.28. Current production cycles for orphan drugs are concentrated with external contractors during the update of digital analysis systems. The business model relies on the total outsourcing of drug synthesis, leaving only marketing and R&D to the firm. The development of therapies for rare pathologies is based on strategic partnerships with scientific foundations.

ZVRA (Kempharm) EV/EBITDA Multiple history from 11/23/2025 to 11/15/2026

ZVRA (Zevra Therapeutics Inc): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Zevra Therapeutics, Inc.|ZVRA - Broker Consensus Forecast
- issuer market value details:
Market Capitalization Zevra Corp|ZVRA - Total Enterprise Value
- issuer book value statistics:
Accounting Value per Share Zevra Therapeutics|ZVRA - Book Capitalization|Market Value to Book Value Ratio zevra.com|ZVRA - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Zevra Therapeutics|ZVRA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Kempharm|ZVRA - Company Debts|Debt to Book Capitalization Ratio Zevra Corp|ZVRA - Long-Term Debt|Company Short-Term Debts Zevra Therapeutics|Quick Liquidity Indicator zevra.com
- net income and valuation multiples indicators:
ZVRA - Company Net Income|Future Profit Zevra Therapeutics|ZVRA - Market Cap to Net Income|Forward P/E Multiple Zevra Corp|ZVRA - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Zevra Therapeutics, Inc.|ZVRA - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Zevra Therapeutics|ZVRA - Earnings per share for the trailing year|Quarterly EPS earnings growth zevra.com|ZVRA - Earnings growth in current year|Expected earnings per share growth for next year Zevra Therapeutics
- total revenue and sales volume data:
ZVRA - Company Sales Revenue|Company Future Sales Volume Kempharm|ZVRA - Market Cap to Sales Volume|Forward P/S Multiple Zevra Therapeutics Inc
Summary company analytics:ZVRA (Zevra Therapeutics Inc)
Original product of Zevra Therapeutics, Inc.

As a portfolio manager, I use this tool to determine the fair value of assets while accounting for debt load. The EV/EBITDA valuation multiple compares the total enterprise value with operating profit before depreciation and taxes, eliminating accounting distortions. The trend in the EV/EBITDA multiple helps identify when an asset is overbought. For Zevra Therapeutics (ZVRA), such a metric is particularly reliable, as stable demand for orphan drugs minimizes cash flow volatility risks.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jazz Pharmaceuticals plc JAZZ|CYTK: Enterprise Value to Operating Income Before Depreciation|PTC Bio - EV/EBITDA Multiple|Company Value to EBITDA Scholar Rock Corp|CNTA (Centessa Pharmaceuticals plc) - Enterprise Value to EBITDA Ratio|Dyne Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edgewise Therapeutics|RAPP: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alumis Pharma (ALMS)|CTNM - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Larimar Pharma LRMR|Capricor Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TRDA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Channel Therapeutics|MNOV: EV/EBITDA Multiple|Company Value to EBITDA Serina Therapeutics Inc (SER)|Enterprise Value to EBITDA Ratio BTAI|promisneurosciences.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple APUS|EV/EBITDA Multiple AEON Biopharma, Inc. (AEON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NLS Pharma NLSP|Total Company Value to Operating Income Before Depreciation Ratio Bionomics Limited (BNOX)|FSD Pharma Inc. - EV/EBITDA Multiple|RETA - EV/EBITDA Multiple